PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series.

Abstract Aripiprazole (ARP) is a popular antipsychotic drug that has demonstrated ameliorative effects on hyperprolactinemia. However, no study to date has studied the utility of ARP in patients with a long history of schizophrenia and antipsychotic treatment. We therefore examined the effect of partial antipsychotic regimen replacement with ARP on hyperprolactinemia induced by chronic antipsychotic use in patients with schizophrenia.
PMID
Related Publications

Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study.

Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.

Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.

Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.

Authors

Mayor MeshTerms
Keywords

Aripiprazole

Clinical global Impression of Improvement

Global Assessment of Functioning

Prolactin

QOL

Schizophrenia

Journal Title asian journal of psychiatry
Publication Year Start




PMID- 28262171
OWN - NLM
STAT- MEDLINE
DA  - 20170306
DCOM- 20170313
LR  - 20170313
IS  - 1876-2026 (Electronic)
IS  - 1876-2018 (Linking)
VI  - 25
DP  - 2017 Feb
TI  - Partial regimen replacement with aripiprazole reduces serum prolactin in patients
      with a long history of schizophrenia: A case series.
PG  - 36-41
LID - S1876-2018(16)30120-4 [pii]
LID - 10.1016/j.ajp.2016.10.005 [doi]
AB  - AIM: Aripiprazole (ARP) is a popular antipsychotic drug that has demonstrated
      ameliorative effects on hyperprolactinemia. However, no study to date has studied
      the utility of ARP in patients with a long history of schizophrenia and
      antipsychotic treatment. We therefore examined the effect of partial
      antipsychotic regimen replacement with ARP on hyperprolactinemia induced by
      chronic antipsychotic use in patients with schizophrenia. METHODS: Sixteen
      patients with a schizophrenia diagnosis (F2) based on the International
      Classification of Diseases (version 10) were recruited. At months 0, 1, 3, and 6 
      of the study, serum prolactin, body weight, and blood glucose were measured, and 
      QOL and psychotic symptoms were assessed using Global Assessment of Functioning
      scores and Clinical Global Impressions of Improvement (CGI-I) scores. RESULTS:
      Nine patients with an average age of 46.7+/-9.6 years and mean disease duration
      of 15.9+/-10.4 years were included in the final analysis. Serum prolactin levels 
      significantly decreased and GAF and CGI-I scores improved significantly over the 
      6-month period after partial replacement with ARP. Additionally, no changes were 
      observed in body weight or blood glucose over the 6-month period. CONCLUSION:
      Partial antipsychotic regimen replacement with ARP improves hyperprolactinemia,
      and may improve the QOL of patients with a long history of schizophrenia.
      CLINICAL TRIAL REGISTRATION NUMBER: Japan Medical Association, Center for
      clinical trials D: JMA-IIA00245.
CI  - Copyright (c) 2016 Elsevier B.V. All rights reserved.
FAU - Naono-Nagatomo, Keiko
AU  - Naono-Nagatomo K
AD  - Department of Psychiatry, Faculty of Medicine, University of Miyazaki, 5200
      Kihara, Kiyotake-cho, Miyazaki-city, Miyazaki 889-1692, Japan. Electronic
      address: keiko_naono@med.miyazaki-u.ac.jp.
FAU - Naono, Hisao
AU  - Naono H
AD  - Department of Psychiatry, Faculty of Medicine, University of Miyazaki, 5200
      Kihara, Kiyotake-cho, Miyazaki-city, Miyazaki 889-1692, Japan; Department of
      Psychiatry, Miyazaki Prefectural Miyazaki Hospital, 5-30 Kitatakamatsu-cho,
      Miyazaki-city, Miyazaki 880-8510, Japan.
FAU - Abe, Hiroshi
AU  - Abe H
AD  - School of Psychological Science, Health Sciences University of Hokkaido, 1757
      Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan.
FAU - Takeda, Ryuichiro
AU  - Takeda R
AD  - Healthcare and Security Center, University of Miyazaki, 1-1 Gakuen
      Kibanadai-nishi, Miyazaki 889-1692, Japan.
FAU - Funahashi, Hideki
AU  - Funahashi H
AD  - Department of Psychiatry, Faculty of Medicine, University of Miyazaki, 5200
      Kihara, Kiyotake-cho, Miyazaki-city, Miyazaki 889-1692, Japan.
FAU - Uchimura, Daisuke
AU  - Uchimura D
AD  - Uchimura Hospital, 852-1 Tsuruzako, Kobayashi-city, Miyazaki 886-0002, Japan.
FAU - Ishida, Yasushi
AU  - Ishida Y
AD  - Department of Psychiatry, Faculty of Medicine, University of Miyazaki, 5200
      Kihara, Kiyotake-cho, Miyazaki-city, Miyazaki 889-1692, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161013
PL  - Netherlands
TA  - Asian J Psychiatr
JT  - Asian journal of psychiatry
JID - 101517820
RN  - 0 (Antipsychotic Agents)
RN  - 82VFR53I78 (Aripiprazole)
RN  - 9002-62-4 (Prolactin)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*pharmacology
MH  - Aripiprazole/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Hyperprolactinemia/blood/*chemically induced
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Prolactin/*blood
MH  - Schizophrenia/blood/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Aripiprazole
OT  - *Clinical global Impression of Improvement
OT  - *Global Assessment of Functioning
OT  - *Prolactin
OT  - *QOL
OT  - *Schizophrenia
EDAT- 2017/03/07 06:00
MHDA- 2017/03/14 06:00
CRDT- 2017/03/07 06:00
PHST- 2016/03/14 [received]
PHST- 2016/08/25 [revised]
PHST- 2016/10/09 [accepted]
AID - S1876-2018(16)30120-4 [pii]
AID - 10.1016/j.ajp.2016.10.005 [doi]
PST - ppublish
SO  - Asian J Psychiatr. 2017 Feb;25:36-41. doi: 10.1016/j.ajp.2016.10.005. Epub 2016
      Oct 13.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>